Azithromycin, sold for decades under the brand name Zithromax and commonly dispensed as the six-tablet "Z-Pack," is one of the most frequently prescribed antibiotics in the country. Yet the reasoning behind its dose - why the first tablet is bigger than the rest, why children's prescriptions are calculated in milligrams per kilogram while adults get a flat number regardless of size, and why the whole course lasts only three to five days - is rarely explained. This article lays out that reasoning: the pharmacology that shaped the standard regimens, the physiological reason body weight governs pediatric dosing far more than adult dosing, and the safety data that keep the ceiling on this drug lower than many patients assume.

The Standard Adult Regimen: What a Z-Pack Actually Contains

The classic Z-Pack regimen for adults with a routine respiratory infection is 500 mg on day one, followed by 250 mg once daily on days two through five - a total of 1.5 grams over five days. This is a fixed dose. A 68-kilogram adult and a 110-kilogram adult are, in the overwhelming majority of cases, prescribed the identical regimen. For sinusitis, a common alternative is 500 mg once daily for three days. For uncomplicated chlamydial infection, a single 1-gram dose was long the standard, though current CDC guidance (updated in 2021) now recommends doxycycline as the preferred first-line treatment for chlamydia, with azithromycin reserved as an alternative - notably in pregnancy, where doxycycline is avoided. Azithromycin is no longer recommended as part of standard gonorrhea treatment either; CDC guidance changed in 2020 in response to rising resistance, shifting to ceftriaxone alone at a higher dose.

The 250 mg tablet that patients ask about is almost never a standalone regimen. It is the maintenance dose used after a larger loading dose has already been given on day one. Taking only 250 mg tablets from the first day, without the loading dose your physician intended, is not how the regimen was studied and should not be improvised.

Why Children Are Dosed by the Kilogram and Adults Are Not

This is where a common assumption breaks down. Many people searching for azithromycin's "dose by weight" expect a formula that applies to everyone. In practice, weight-based, milligram-per-kilogram dosing is the rule for children and the exception for adults. A typical pediatric regimen for ear infections or pneumonia is 10 mg/kg on day one (up to a maximum of 500 mg), then 5 mg/kg once daily on days two through five (up to a maximum of 250 mg). For strep throat, guidelines often use 12 mg/kg once daily for five days.

The reason children require this calculation is straightforward physiology. A drug's clearance from the body and its volume of distribution scale with body size in ways that do not track neatly with age - a large seven-year-old and a small ten-year-old may need very different absolute doses to achieve the same tissue concentration. Adults, by contrast, occupy a comparatively narrow and stable range of body composition once growth has stopped, and the clinical trials that established azithromycin's approved regimens tested fixed doses across that adult range and found them effective without needing to scale further for larger patients. This is also why, for an obese adult, there is no established evidence that increasing the azithromycin dose beyond the standard regimen improves outcomes; the drug's unusually large volume of distribution means it already penetrates deep into tissue regardless of how much additional fat mass a patient carries.

The Pharmacokinetics Behind the Taper: Why Days Instead of Weeks

Azithromycin belongs to a class called macrolides, and more specifically to a subclass called azalides - the product of a small but consequential change made to the erythromycin molecule. Erythromycin itself was isolated from Streptomyces erythreus, a bacterium recovered from a soil sample in the Philippines in the late 1940s, a reminder that some of modern medicine's most useful tools were quietly present in the created world long before anyone knew to look for them. Chemists later modified erythromycin's structure to produce azithromycin, which behaves very differently in the body.

Unlike most antibiotics, azithromycin does not stay mainly in the bloodstream. It concentrates heavily inside cells - particularly white blood cells called phagocytes and fibroblasts - which then ferry it directly to sites of infection and inflammation. Classic pharmacokinetic work from the early 1990s (Foulds and colleagues, published in the Journal of Antimicrobial Chemotherapy, 1990) demonstrated that tissue concentrations of azithromycin can remain many times higher than concurrent blood concentrations, and that the drug's effective tissue half-life extends to roughly 68 hours - several days longer than most antibiotics in common use. That is why a short course, front-loaded with a larger first dose, achieves and sustains therapeutic tissue levels for a week or more after the last tablet is swallowed, even though blood levels fall quickly. It is also the basis for an extended-release single-dose formulation (marketed at times as Zmax) that delivers an entire course as one 2-gram dose, relying on the same slow tissue clearance to do the work that a multi-day course would otherwise do.

Safety Considerations That Shape the Dose

Dosing decisions are never made in isolation from safety, and azithromycin has a genuine, well-documented cardiac consideration. A large retrospective cohort study led by researchers at Vanderbilt University, published in the New England Journal of Medicine in 2012, examined Tennessee Medicaid data and found a small but statistically significant increase in cardiovascular death during the five-day course of azithromycin compared with amoxicillin, driven by the drug's known effect on cardiac electrical repolarization (QT prolongation). The increase was concentrated among patients who already had elevated baseline cardiovascular risk; for most healthy patients the absolute risk was very low. The FDA responded in 2013 with a formal drug safety communication reinforcing caution in patients with existing QT prolongation, low potassium or magnesium, significant bradycardia, or concurrent use of other drugs known to affect heart rhythm.

This is one reason physicians do not simply raise the azithromycin dose in larger patients the way they might with, say, weight-based dosing of an anticoagulant. The therapeutic window is narrower than the drug's excellent tissue penetration might suggest, and the standard adult doses were chosen to balance efficacy against this cardiac signal.

Matching the Regimen to the Infection - and Finishing It

The correct azithromycin dose is not one number but a family of regimens, each matched to a specific infection, patient age, and body weight where relevant:

Whatever the regimen, finishing the full course as prescribed matters for reasons beyond the individual patient. Stopping early because symptoms improve after two days can leave partially resistant bacteria behind - a small contribution to a larger, cumulative problem of antibiotic resistance that affects entire communities, including people more vulnerable than the original patient: infants, the elderly, and those undergoing treatments like chemotherapy that depend on antibiotics still working. Taking personal responsibility for finishing a prescribed course, and asking a physician directly when something about the regimen seems unclear, is a small but real act of stewardship - both of one's own health and of a medical tool that future patients will also need.

Key takeaway: azithromycin's dose is calculated from body weight in children, from fixed clinical-trial regimens in adults, and from tissue pharmacokinetics in both cases - so the right dose for any individual patient is the one their own physician prescribes, not a number pulled from a chart.